EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab

Sven G Meuth, Stephanie Wolff, Anna Mück, Alice Willison, Konstanze Kleinschnitz, Saskia Räuber iD, Marc Pawlitzki, Franz Felix Konen, Thomas Skripuletz, Matthias Grothe iD, Tobias Ruck, Hagen B Huttner und 7 weitere

Annals of Neurology · 2025

DOI: 10.1002/ana.27143 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Annals of Neurology, 2025. Verfasst von Sven G Meuth und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

B‐cell–depletion via CD20 antibodies is a safe and effective treatment for active relapsing multiple sclerosis (RMS). Both ocrelizumab (OCR) and ofatumumab (OFA) have demonstrated efficacy in randomized controlled trials and are approved for treatment of RMS, yet nothing is known on their comparative effectiveness, especially in the real‐world setting.

Methods

This prospective cohort study includes patients that were started on either OCR or OFA between September 2021 and December 2023. Patients were followed until June 2024 and recruited at 3 large tertiary centers in Germany (Duesseldorf, Essen, and Giessen). Propensity‐score‐matching was used to address baseline imbalances among patients. Clinical relapses, presence of new or enlarging MRI lesions and 6‐month confirmed disability worsening were evaluated. Non‐inferiority of OFA compared to OCR was evaluated through comparison of Kaplan–Meier‐estimates.

Results

A total of 1,138 patients were initially enrolled in the cohort. Following patient selection and propensity‐score‐matching, 544 OCR and 417 OFA patients were included in the final analysis. In our primary analysis, OFA was non‐inferior to OCR in terms of relapses, disability progression, and accrual of MRI lesions. Subgroup analyses confirmed findings in previously naïve and platform‐treated patients. Potential differences between OFA and OCR were seen in patients switching from S1P receptor modulators or natalizumab.

Conclusion

We here provide comparative data on the effectiveness of OCR and OFA in patients with active RMS. OFA was non‐inferior to OCR in the overall cohort. Potential differences observed in patients switching from S1P receptor modulators or natalizumab require further validation. ANN NEUROL 2025;97:583–595

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunologic FactorsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdultFemaleHumansMaleMiddle AgedCohort StudiesProspective StudiesTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedImmunologic Factorsocrelizumabofatumumab

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
  • Department of Neurology, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Giessen, Germany.
  • Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, Duisburg, Germany.
  • Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Department of Neurology, University Medicine Greifswald, Greifswald, Germany.
  • Institute of Immunology, University Medical Center Mainz, Mainz, Germany.

ORCID-Profile: Saskia Räuber, Matthias Grothe, Bruce A C Cree, Hans-Peter Hartung, Steffen Pfeuffer

Zitieren

APA

Meuth, S. G., Wolff, S., Mück, A., Willison, A., Kleinschnitz, K., Räuber, S., Pawlitzki, M., Konen, F. F., Skripuletz, T., Grothe, M., Ruck, T., Huttner, H. B., Kleinschnitz, C., Bopp, T., Pul, R., Cree, B. A. C., Hartung, H. P., Möllenhoff, K., & Pfeuffer, S. (2025). Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab. Annals of Neurology. https://doi.org/10.1002/ana.27143

Vancouver

Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, et al. Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab. Annals of Neurology. 2025. doi:10.1002/ana.27143

BibTeX
@article{Meuth2025,
  author = {Meuth, Sven G and Wolff, Stephanie and Mück, Anna and Willison, Alice and Kleinschnitz, Konstanze and Räuber, Saskia and Pawlitzki, Marc and Konen, Franz Felix and Skripuletz, Thomas and Grothe, Matthias and Ruck, Tobias and Huttner, Hagen B and Kleinschnitz, Christoph and Bopp, Tobias and Pul, Refik and Cree, Bruce A C and Hartung, Hans-Peter and Möllenhoff, Kathrin and Pfeuffer, Steffen},
  title = {Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab},
  journal = {Annals of Neurology},
  year = {2025},
  doi = {10.1002/ana.27143}
}
Kostenlos starten →